A multinational pharmaceutical company is looking for novel technologies or methodologies that allow antibody-drug conjugation. Specifically, our client is interested in novel linker conjugation technologies for mAB conjugation with conventional small molecule drugs. Approaches should use novel methods that provide improved serum stability and physicochemical properties compared to conventional conjugation methods.
Approaches of Interest
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.